China SXT Pharmaceuticals (FRA:2RY2) Growth Rank: 0 (As of Aug. 13, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2RY2 China SXT Pharmaceuticals Inc FRA:2RY2
19 GF Score
Price €3.04
GF Value €5.74
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is China SXT Pharmaceuticals Growth Rank?

China SXT Pharmaceuticals has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

China SXT Pharmaceuticals Growth Rank Related Terms

FRA:2RY2
19GF Score
China SXT Pharmaceuticals Inc FRA:2RY2
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is China SXT Pharmaceuticals (FRA:2RY2) Overvalued in 2026?

Based on GuruFocus' analysis, China SXT Pharmaceuticals stock appears to be undervalued. The current stock price of €3.04 is trading 47.1% below its estimated GF Value™ of €5.74. GuruFocus considers China SXT Pharmaceuticals to be Possible Value Trap.

Key valuation signals for FRA:2RY2:

  • Growth Rank: 0
  • GF Value™: €5.74 vs. price of €3.04 (47.1% below fair value)
  • GF Score™: 19/100 with 8 warning signs

No single metric tells the full story. See the FRA:2RY2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China SXT Pharmaceuticals Business Description

Other Exchanges SXTC:USA
Address No. 178 Taidong Road North, Jiangsu, Taizhou, CHN, 225300
China SXT Pharmaceuticals Inc is a pharmaceutical company that is focused on the research, development, manufacture, marketing, and sales of Traditional Chinese Medicine Pieces (TCMP), particularly, TCMP (Directed-oral TCMP, and After-soaking TCMP) which is a sort of Traditional Chinese Medicine (TCM) that has been processed to be ready for use without decoction. Geographically, the firm generates its revenue from the People's Republic of China.
19GF Score

Get the complete analysis for FRA:2RY2

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.04
Price
€5.74
GF Value